Mancebo HA, González RA, González SN, Lombardo AE

Language: Spanish
References: 18
Page: 66-72
PDF size: 157.91 Kb.

ABSTRACT

Background. An epidemic outbreak of infection by parvovirus B19 (infectious erythema), took place in the National Institute of Pediatrics. This is a relatively new disease, rarely diagnosed or notified to the Health Services in Mexico. A clinical and epidemiologic study was carried out which limited and controlled the magnitude and importance of the event.
Material and methods. Observational and longitudinal study from the 09th of May to the 24th of June, 2005. A survey was conducted which included clinical criteria (signs and symptoms), epidemiologic criteria (operational definitions) and laboratory tests (antibody IgM for parvovirus B19). Measures for prevention of transmission and for the control of the disease were implemented.
Results. Of a susceptible population of 155 people, 74.8% women and 25.2% men, of zero to 64 years old studied, 25 were workers: Doctors, nurses and administrative employees, ages 25 to 44 years. Nine were suspected of infection and 16 as probable cases; 24 IgM serologic determinations for parvovirus B19 were done; 17 were negative and 7 positive.
Conclusions. This outbreak of infection by parvovirus B19, was limited to the Emergency Room; it lasted 25 days. The infection was propagated by respiratory transmission. Its incubation period was 12 days. The incidence was 7 cases (resident doctors); the overall incidence was 4.5%. No children were affected and there were no fatalities. This outbreak was controlled with adequate and opportune measures, i.e. use of face masks, hand washing by the entire staff which interrupted the transmission. Epidemiologic Surveillance at the hospital was enhanced.

REFERENCES

1. Secretaria de Salud/Sistema Nacional de Vigilancia Epidemiológica. 2ª. Edición, México, 2001

2. NOM-017-SSA2-1994 Para la Vigilancia Epidemiológica en México

3. Lemus J, Clovis H, Ruiz P, et al. Manual de Vigilancia Epidemiológica. OPS/OMS/Fundación W.K. Kellog 05/31/2005.

4. Pickering B, Overturf P. Red Book: Enfermedades Infecciosas en Pediatría. 26ª. Ed. Buenos Aires, Ed. Medica Panamericana, 2004;pp535-8

5. González N, Torales N, Demóstenes G, Sapián A, Pérez E. Infectología Clínica Pediátrica, 7ª. Ed, Mc Graw Hill, México 2004;pp753-57

6. Behrman R, Kliegman R, Jenson H. Tratado de Pediatría, Nelson. 16ª. Edición. Mc Graw Hill. México, 2001;pp1058-61

7. Anand A, Gray ES, Brown T. Human parvovirus infection in pregnancy and hydrops fetalis. N Engl J Med 1987;316:183

8. Miller E, Fairley CK, Cohen BJ, et al. Immediate and long-term outcome of human parvovirus B19 infection in pregnancy. Br J Obstet Gynaecol 1998;105:174-8

9. Anderson LJ, Tsou C, Parker TL, et al. Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. J Clin Microbiol 1986;24;522-6

10. Chin J. El control de las enfermedades transmisibles en el hombre. OPS, Washington, 2002

11. Katta R. Parvovirus B19: a review. Dermat Clin 2002;20:13-24

12. Nocton JJ, Miller LC, Tucker LB, et al. Human parvovirus B19-associated arthritis in children. J Pediatr 1993;122:186-90.

13. Heegasrd ED, Rosthoj S, Petersen BL, et al. Role of parvovirus B19 infection in childhood idiopathic thrombocytopenic purpura. Acta Pediatr 1999;88:614-7

14. Cohen BJ, Bukley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 1988;25:151-3

15. Kelly HA, Siebert D, Hammond R, et al. The age-specific prevalence of human parvovirus immunity in Victoria, Australia, compared with other parts of the world. Epidemiol Infec 2000;124:449-57

16. Sabelle C. Parvovirus B19 infection. American Fam Physician 1999;60:1455-60

17. Brown R. Human parvovirus B19. En: Long S, Pickering L, Principles and Practice of Pediatric Infectious Diseases 2a. Ed, 2003;pp1101-3

18. Borreda D, Palomera S, Gilbert B, et al. 24 cases of human parvovirus B19 infection in children. Ann Pediatr (Paris) 1992;39:543-9